| |
|
|
|
Proqr Therapeutics  
|
|
4.715 0.365 (0.08%) |
02-24 14:58 |
|
Open: |
4.48 |
Pre close: |
4.35 |
Target:
|
6.38
|
|
High: |
4.84 |
Low: |
4.41 |
Resistance:
|
5.47
6.34
|
|
Volume: |
443,158 |
Market Cap: |
236M |
Support:
|
4.05
3.37
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
4.68
 |
MACD |
MACD(12,26):
|
0.00 |
|
MA(20): |
4.89 |
Signal(12,26,9): |
0.08 |
|
MA(100): |
4.42 |
Stochastic Oscillator |
%K(14,3):
|
24.17 |
|
MA(250): |
5.08 |
%D(3): |
26.08 |
|
Average Volume(K) |
3-Month: |
68094
|
52-Week |
High:
|
8.69 |
|
10-Days: |
57268 |
Low: |
3.40 |
|
RSI |
RSI(14):
|
48.18  |
Change(%): |
-31.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.308 |
Return on Equity (ttm) |
-81.5 |
Shares Out. (M) |
50.15 |
|
EPS Est. Current Year |
-2.110 |
Return on Assets (ttm) |
-36.9 |
Shares Float (M) |
36.79 |
|
EPS Est. Next Year |
-1.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.95 |
|
EPS Est. Next Quarter |
-0.520 |
Qtrly Rev. Growth |
-52.6 |
% Held by Institutions |
69.26 |
|
Forward EPS |
-1.241 |
Gross Profit (p.s.) |
0.038 |
Shares Short (K) |
1110 |
|
Book Value (p.s.) |
3.090 |
EBITDA (p.s.) |
0.000 |
P/E |
-3.60 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.52 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
0.00 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
0.00 |
|
|
|
|
|
|
